LRRC32 antibody (APC)

Catalog No. ABIN2658317

The APC-conjugated Mouse Monoclonal anti-LRRC32 antibody (Clone 7B11) (ABIN2658317) specifically detects LRRC32 in BCA. The antibody is reactive with Human samples.

Quick Overview for LRRC32 antibody (APC) (ABIN2658317)

Target: LRRC32 (Leucine Rich Repeat Containing 32 (LRRC32))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This LRRC32 antibody is conjugated to APC

Application: Biochemical Assay (BCA)

Clone: 7B11

Product Details anti-LRRC32 Antibody (APC)

Purification: The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions. The solution is free of unconjugated APC and unconjugated antibody.

Isotype: IgG2b kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from prolonged exposure to light. Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for LRRC32

Target: LRRC32 (Leucine Rich Repeat Containing 32 (LRRC32))

Alternative Name: GARP

Background: Glycoprotein A Repetitions Predominant (GARP), also known as leucine rich repeat containing 32 (LRC32), is a 80 kD type I membrane glycoprotein with 20 leucine rich repeats in the extracellular portion of the protein. GARP was found on the surface of megakaryocytes, platelets, and activated Tregs (CD4+, CD25+, FoxP3+ cells) and serves as a receptor for latent TGF-β. Recent evidence suggests that GARP may play a role in controlling suppressor function of Tregs. A mutation in GARP has been reported in a large Samaritan kindred with Usher syndrome type 1, an autosomal recessive disease characterized by profound congenital sensorineural deafness, vestibular dysfunction, and progressive visual loss. In addition, it has been found that GARP mRNA is highly amplified in different tumors, which indicates that tumor cells may use GARP to express TGF-β or to capture TGF-β from their surroundings, resulting in local suppression of anti-tumor immune responses or the induction of Tregs.

Pathways: Activated T Cell Proliferation